Clinical Epidemiology of Cardiac Disease in Dialysis Patients: Left Ventricular Hypertrophy, Ischemic Heart Disease, and Cardiac Failure

Seminars in Dialysis

Volumn 16, Issue 2, 2003, Pages 111-117

  Foley, Robert N ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HEMOGLOBIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PHOSPHATE BINDING AGENT; PLACEBO; PRAVASTATIN; SEVELAMER;

ANEMIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMODYNAMICS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIPID BLOOD LEVEL; METABOLISM; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; SMOKING; STROKE; UREMIA; VITAMIN SUPPLEMENTATION; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; HEART MUSCLE ISCHEMIA; HYPERLIPIDEMIA; KIDNEY DISEASE; RENAL REPLACEMENT THERAPY;

ANEMIA; CHRONIC DISEASE; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERLIPIDEMIAS; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; KIDNEY DISEASES; MYOCARDIAL ISCHEMIA; PREVALENCE; PROGNOSIS; RENAL DIALYSIS; SMOKING;

EID: 0037489824     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139X.2003.160271.x     Document Type: Review

References (74)

1. Foley RN, Herzog CA, Collins AJ: Smoking and cardiovascular outcomes in dialysis patients. The United States Renal Data System Wave 2 Study. Kidney Int: (in press), 2002
2. Foley RN, Parfrey PS, Harnett JD. Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting endstage renal disease therapy. Kidney Int 47:186-192, 1995
3. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12:2759-2767, 2001
4. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS, Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12:2768-2774, 2001
5. Berger CJ, Murabito JM, Evans JC, Anderson KM, Levy D: Prognosis after first myocardial infarction. Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA 268:1545-1551, 1992
6. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61:2235-2239, 2002
7. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 54:1720-1725, 1998
8. Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL. Foss A, Fauchald P, Holdaas H: Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 72:107-111, 2001
9. Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD: Impact of renal transplantation on uremic cardiomyopathy. Transplantation 60:908-914, 1995
10. Rigatto C, Foley RN, Kent GM, Guttmann R, Parfrey PS: Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 70:570-575, 2000
11. Unger P, Wissing KM, de Pauw L, Neubauer J. van de Borne P: Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients. Transplantation 74:73-79, 2002
12. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC. Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11:912-916, 2000
13. Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis 20(5 suppl 2):32-38, 1992
14. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47:884-890, 1995
15. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 37:484-489, 2001
16. Bloembergen WE, Stannard DC, Port FK, Wolfe RA, Pugh JA, Jones CA. Greer JW, Golper TA, Held PJ: Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 50:557-565, 1996
17. Kasiske BL, Klinger D: Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 11:753-759, 2000
18. Orth SR: Smoking and the kidney. J Am Soc Nephrol 13:1663-1672, 2002
19. The prevention or delay of type 2 diabetes. American Diabetes Association. Diabetes Care 25:742-749, 2002
20. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75:894-903, 1995
21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998
22. Manske CL, Wilson RF, Wang Y, Thomas W: Prevalence of and risk factors for angiographically determined coronary artery disease in type I-diabetic patients with nephropathy. Arch Intern Med 152:2450-2455, 1992
23. Makita Z, Bucala R, Winston JA, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM: Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet 343:1519-1522, 1994
24. Koznarova R, Saudek F, Sosna T, Adamec M, Jedinakova T, Boucek P, Bartos V, Lanska V: Beneficial effect of pancreas and kidney transplantation on advanced diabetic retinopathy. Cell Transplant 9:903-908, 2000
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
26. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252-1256, 1998
27. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
28. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316:1429-1435, 1987
29. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325:293-302, 1991
30. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 327:685-691, 1992
31. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG: Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 18:41-51, 1997
32. U.S. Renal Data System: USRDS 1992 annual report. IV. Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis (suppl 2):32-38, 1992
33. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
34. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49:1379-1385, 1996
35. Peixoto AJ, Santos SF, Mendes RB, Crowley ST, Maldonado R, Orias M, Mansoor GA, White WB: Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients. Am J Kidney Dis 36:983-990, 2000
36. Levin A, Sinder J, Tompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
37. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR: Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 12:724-728, 1997
38. Rahman M, Dixit A, Donley V, Gupta S, Hanslik T, Lacson E, Ogundipe A, Weigel K, Smith MC: Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients [see comments]. Am J Kidney Dis 33:498-506, 1999
39. Fishbane S, Natke E, Maesaka JK: Role of volume overload in dialysis-refractory hypertension. Am J Kidney Dis 28:257-261, 1996
40. Scribner BH: Can antihypertensive medications control BP in haemodialysis patients: yes or no? Nephrol Dial Transplant 14:2599-2601, 1999
41. Fagugli RM, Reboldi G, Quintaliani G, Pasini P, Ciao G, Cicconi B, Pasticci F, Kaufman JM, Buoncristiani U: Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 38:371-376, 2001
42. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cache JL: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 90:2786-2796, 1994
43. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 103:1245-1249, 2001
44. Asmar R, Rudnichi A, Blacher J, London GM, Safar ME: Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations. Am J Hypertens 14:91-97, 2001
45. Tozawa M, Iseki K, Iseki C, Takishita S: Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 61:717-726, 2002
46. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF Jr: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287:1548-1555, 2002
47. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 study. Kidney Int 62:1784-1790, 2002
48. London GM, Guerin AP, Marchais SJ, Pannies B, Safar ME, Day M, Metivies F: Cardiac and arterial interactions in end-stage renal disease. Kidney Int 50:600-608, 1996
49. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
50. Goldwasser P, Michel MA, Collier J, Mittman N, Fein PA, Gusik SA. Avram MM: Prealbumin and lipoprotein (a) in hemodialysis: relationship with patients and vascular access survival. Am J Kidney Dis 22:215-225, 1993
51. Wanner C, Krane V, Ruf G, Marz W, Ritz E: Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int 71:S222-S226, 1999
52. Baigent C, UK-Harp Steering Committee: Efficacy and safety of simvastatin and low-dose aspirin among patients with chronic renal disease: the UK-Heart and Renal Protection (UK-HARP) pilot study [abstract]. J Am Soc Nephrol 12:190A, 2001
53. Tonelli M, Moye L, Sacks F, Curhan G: Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency [abstract]. J Am Soc Nephrol 12:252A, 2001
54. Muirhead N, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, Parfrey P: Evidence-based recommendations for the clinical use of human erythropoietin. Am J Kidney Dis 26(suppl 1):S1-S24, 1995
55. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
56. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61, 1996
57. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 8:1921-1929, 1997
58. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
59. Besarab A, Kline Bolton W, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
60. Katz AM: The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med 121:363-371, 1994
61. Hunter JJ, Chien KR: Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341:1276-1283, 1999
62. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000
63. McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D: Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 14:1182-1187, 1999
64. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15:1425-1430, 2000
65. Middleton RJ, Parfrey PS, Foley RN: Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 12:1079-1084, 2001
66. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME, Metivier F, Llach F: Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 31:973-980, 1987
67. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617, 1998
68. Guerin AP, London GM. Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021, 2001
69. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
70. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35:469-476, 2000
71. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 7:728-736, 1996
72. Kaysen GA: The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12:1549-1557, 2001
73. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356:1213-1218, 2000
74. Bostom AG, Culleton BF: Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 10:891-900, 1999